Literature DB >> 31526650

Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?

Francesco Soria1, David D'Andrea2, Marco Moschini3, Andrea Giordano4, Simone Mazzoli4, Giuseppe Pizzuto4, Rodolfo Hurle5, Renzo Colombo6, Alberto Briganti6, Vincenzo Altieri7, Shahrokh F Shariat8, Paolo Gontero4.   

Abstract

PURPOSE: To evaluate the predictive factors of pT0 at repeated transurethral resection of the bladder (re-TURB) in pT1 high-grade (HG) nonmuscle invasive bladder cancer in order to explore the possibility to avoid it in well-selected patients.
METHODS: This multicenter retrospective study included patients with pT1HG nonmuscle invasive bladder cancer from 4 different centers who underwent a complete TURB. Re-TURB was defined as a second resection which involved the site of the first TURB performed within 2-6 weeks from the previous resection. A multivariable logistic-regression model was performed to evaluate the predictors of pT0 at re-TURB. A nomogram was built to calculate the probability of obtaining a negative histology at re-TURB. The performance of the nomogram and its net benefit were tested with the decision curve analysis.
RESULTS: Overall, 321 patients were included in the study. On multivariable logistic regression, detrusor muscle in the specimen (HR 1.99, P = 0.02), concomitant carcinoma in situ (HR 0.29, P = 0.005) and resection performed with en-bloc technique (HR 7.71, P = 0.01) were independent predictors of pT0 at re-TURB. Decision curve analysis showed a net benefit for the nomogram for each probability over 0.35 compared to the strategy to perform a re-TURB in all pT1HG tumors.
CONCLUSIONS: The presence of detrusor muscle in TURB specimen, the absence of concomitant carcinoma in situ and the en-bloc resection were able to predict a negative histology at re-TURB, opening the door to the possibility to avoid it in an extremely well-selected cohort of patients. External validations and prospective studies are urgently needed.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Nomogram; Predictive factors; Re-TURB; Second look TURB; T1HG bladder cancer

Mesh:

Year:  2019        PMID: 31526650     DOI: 10.1016/j.urolonc.2019.08.010

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  7 in total

1.  When to Avoid a Restaging Procedure for Non-muscle Invasive Bladder Cancer? Inferences from a Tertiary Care Center.

Authors:  Deepak Prakash Bhirud; Ankur Mittal; Sunil Kumar; Tushar Aditya Narain; Sanjeev Kishore; Shiv Charan Navriya; Satish Kumar Ranjan; Vikas Kumar Panwar
Journal:  Indian J Surg Oncol       Date:  2022-03-18

2.  Could We Safely Avoid a Second Resection in Selected Patients With T1 Non-Muscle-Invasive Bladder Cancer? Preliminary Results of Cost-Effectiveness Study From HUmanitas New Indications for ReTUR (HuNIRe) Multicenter Prospective Trial.

Authors:  Roberto Contieri; Giovanni Lughezzani; Nicolò Maria Buffi; Gianluigi Taverna; Alessandro Giacobbe; Emanuele Micheli; Sabato Barra; Piergiuseppe Colombo; Elena Vanni; Giorgio Guazzoni; Massimo Lazzeri; Rodolfo Hurle
Journal:  Front Oncol       Date:  2022-05-18       Impact factor: 5.738

Review 3.  Can a reresection be avoided after initial en bloc resection for high-risk nonmuscle invasive bladder cancer? A systematic review and meta-analysis.

Authors:  Jiangnan Xu; Zhenyu Xu; HuMin Yin; Jin Zang
Journal:  Front Surg       Date:  2022-09-14

Review 4.  Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR).

Authors:  Mihaela Georgiana Musat; Christina Soeun Kwon; Elizabeth Masters; Slaven Sikirica; Debduth B Pijush; Anna Forsythe
Journal:  Clinicoecon Outcomes Res       Date:  2022-01-10

5.  Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer.

Authors:  David D'Andrea; Francesco Soria; Anne J Grotenhuis; Eugene K Cha; Nuria Malats; Savino Di Stasi; Steven Joniau; Tommaso Cai; Bas W G van Rhijn; Jaques Irani; Jeffrey Karnes; John Varkarakis; Jack Baniel; Joan Palou; Marek Babjuk; Martin Spahn; Peter Ardelt; Renzo Colombo; Vincenzo Serretta; Guido Dalbagni; Paolo Gontero; Riccardo Bartoletti; Stephane Larré; Per-Uno Malmstrom; Richard Sylvester; Shahrokh F Shariat
Journal:  World J Urol       Date:  2021-03-13       Impact factor: 4.226

6.  Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.

Authors:  David D'Andrea; Surena Matin; Peter C Black; Firas G Petros; Homayoun Zargar; Colin P Dinney; Michael S Cookson; Wassim Kassouf; Marc A Dall'Era; John S McGrath; Jonathan L Wright; Andrew C Thorpe; Todd M Morgan; Jeffrey M Holzbeierlein; Trinity J Bivalacqua; Srikala S Sridhar; Scott North; Daniel A Barocas; Yair Lotan; Andrew J Stephenson; Bas W van Rhijn; Philippe E Spiess; Siamak Daneshmand; Shahrokh F Shariat
Journal:  BJU Int       Date:  2020-10-14       Impact factor: 5.588

7.  Long-term Follow-up After En Bloc Transurethral Resection of Non-muscle-invasive Bladder Cancer: Results from a Single-center Experience.

Authors:  Marco Paciotti; Paolo Casale; Piergiuseppe Colombo; Vittorio Fasulo; Alberto Saita; Giovanni Lughezzani; Roberto Contieri; Nicolò Maria Buffi; Massimo Lazzeri; Giorgio Guazzoni; Rodolfo Hurle
Journal:  Eur Urol Open Sci       Date:  2021-02-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.